Membranous glomerulonephritis, psoriasis and etanercept. A chance or causal association?

Nefrologia. 2012;32(2):228-32. doi: 10.3265/Nefrologia.pre2011.Nov.11112. Epub 2012 Mar 16.
[Article in English, Spanish]

Abstract

Psoriasis is a cutaneous disease with systemic involvement. Tissue damage is considered to be immune-mediated, and etanercept currently provides effective treatment. Kidney injury arising from this condition has not yet been fully explained in the literature. We present a case of membranous nephropathy with C1q deposits followed by development of psoriasis. In this article we will review the possible association between these conditions and the response to this biological molecule.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Etanercept
  • Glomerulonephritis, Membranous / complications*
  • Glomerulonephritis, Membranous / drug therapy*
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Psoriasis / drug therapy*
  • Psoriasis / etiology*
  • Receptors, Tumor Necrosis Factor / therapeutic use*

Substances

  • Immunoglobulin G
  • Immunosuppressive Agents
  • Receptors, Tumor Necrosis Factor
  • Etanercept